CASSAVA SCIENCES INC

For the period ended Dec 31, 2024. Filed Mar 3, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 3, 2025

FLNA$0.49+8.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share and par value data)

	December 31,
	2024	2023
ASSETS
Current assets:
Cash and cash equivalents	$128,574	$121,136
Prepaid expenses and other current assets	7,958	8,497
Total current assets	136,532	129,633
Property and equipment, net	20,964	21,854
Intangible assets, net	37	176
Total assets	$157,533	$151,663
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and other accrued expenses	$7,654	$10,573
Accrued development expense	2,440	3,037
Accrued compensation and benefits	1,357	200
Other current liabilities	299	385
Total current liabilities	11,750	14,195
Other non-current liabilities	79	—
Total liabilities	11,829	14,195
Commitments and contingencies (Notes 10, 11 and 12)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding	—	—
Common stock, $0.001 par value; 120,000,000 shares authorized; 48,203,179 and 42,236,919 shares issued and outstanding at December 31, 2024 and 2023, respectively	48	42
Additional paid-in capital	550,767	518,195
Accumulated deficit	(405,111)	(380,769)
Total stockholders' equity	145,704	137,468
Total liabilities and stockholders' equity	$157,533	$151,663

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.